Leadership

Stephen J. Trevisan, President and CEO, Accelovance

Mr. Trevisan is an entrepreneur who has founded four companies, including Accelovance in 2004.

Prior to Accelovance, Mr. Trevisan founded TherImmune Research Corp. (TherImmune), a CRO specializing in pre-clinical and early stage clinical drug-development services for the pharmaceutical, biotechnology and government markets. He also founded CommSys Corp., a provider of outsourced billing services to the telecommunications industry. In 1987 Mr. Trevisan co-founded his first company, National Clinical Research Centers (NCRC). NCRC was a clinical Contract Research Organization (CRO) specializing in Phase II-IV clinical studies. NCRC deployed a unique method for running clinical trials, which was successful in reducing the time frame in conducting multi-center trials in broad-based indications.

Each of Mr. Trevisan’s prior companies maintained year-over-year growth and were ultimately acquired by public companies.

Ken K. Ren, MD, PhD, President, Accelovance, China

Dr. Ren, M.D., Ph.D., has been the founder and key manager of several U.S.-based start-up companies in pharmaceutical development or services in both China and the United States over the past 10 years. Prior to Accelovance, Dr. Ren was the founder of New Jersey-based AHT Inc., which merged with Novemed, a portfolio investment of a blue-chip public company in Hong Kong.

Dr. Ren was a co-founder of China Innovation Center for Life Science (U.S.A.) Corp., a New York-based consulting firm in partnership with the Chinese Ministry of Science and Technology. It provided consulting services to health-care and pharmaceutical industries in both China and the United States from 1996 to 1999. Its clients included such multinational companies as Johnson & Johnson, Novartis, Bristol-Myers Squibb, Pfizer and Covance. The company also succeeded in advising several Chinese companies to receive investigational new drug (IND) application allowance from the U.S. Food and Drug Administration as well as intellectual-property applications.

Stephan A. Bart Sr., MD, CPI, Chief Medical Officer

Dr. Bart leads medical affairs for both the Clinical Site and CRO divisions of the organization. He is Board Certified in Family Medicine with a sub-specialty in Women’s Health and has been active as a clinical physician and researcher for more than 16 years. Prior to joining Accelovance, Dr. Bart held a senior executive position and was a member of the Board of Directors at Idis, Inc., a global organization with expertise in named patient programs (NPPs). He also served as Chief Medical Officer at SNBL Clinical Pharmacology Center, a Phase I unit in Baltimore, Maryland. Dr. Bart is aligned with the innovative thinking of Accelovance and commitment to improving both predictability and quality of study conduct; enhancing the level of clinical solutions Accelovance can provide to clients.

In addition to protocol development and international regulatory interactions, Dr. Bart has developed and managed teams for Quality Assurance, Medical Information, Medical Affairs, Regulatory Compliance and Study Management. Additional areas of therapeutic expertise include infectious disease, immunology, Women’s Health, metabolic disease, orphan drug development, oncology, rheumatoid disease. Dr. Bart completed his undergraduate work at the University of Illinois and University of Northeastern Illinois, graduating with a Bachelor of Science in Biology and Chemistry. He received his Medical Degree from Rush University Medical College and further postgraduate training at the University of Pittsburgh and the University of South Florida. Dr. Bart has held faculty positions at Penn State University as well as the University of Maryland Medical Center.

EB McLindon, Chief Operating Officer

Mr. McLindon is responsible for aligning Accelovance’s CRO and Patient Recruitment divisions with the defined objectives of each study and also a Sponsor’s overall business strategy. Blending innovative thinking and outside-the-industry perspective along with common industry practices, Accelovance differentiates itself from other organizations. Mr. McLindon offers an unbiased logic to evaluate the operational execution of clinical programs; accounting for patient, clinical site, vendor and Sponsor needs to ensure the right clinical solution is deployed. Over the past 7 years with Accelovance, Mr. McLindon has implemented study approaches that accelerate study timelines, increase predictability, ensure quality and operate within budget. He joined the industry in 2005 after a series of positions with escalating responsibility in a range of industries from Finance, IT, Commercial Real Estate, Private Investment and Clinical Research.

Joseph W. Angle Jr., Chief Financial Officer

Mr. Angle leads the financial, legal and administrative functions for the company. Mr. Angle has over 17 years of experience in the drug development, pre-clinical and clinical research industries. He previously co-founded several companies with Accelovance CEO Stephen J. Trevisan, including TherImmune Research Corp., CommSys Corp. and National Clinical Research Centers (NCRC). He served in a similar capacity at Computer Sciences Corporation, as part of the Health and Administrative Services Division based in Washington, DC, a claims processing service organization for the federal and state governments. Mr. Angle helped manage each company to profitability and year over year revenue growth.

Garrett D. Smith, Vice President, Business Development

Mr. Smith has been with Accelovance since 2005 and currently leads corporate marketing and business development responsibilities. Mr. Smith has hands-on experience supporting the Phase I-IV clinical research needs of Sponsors, clinical sites and CROs. His career in this industry began in patient recruitment, leveraging a background in marketing and sociology to implement novel, more cost-effective recruitment campaigns. Since joining Accelovance, Mr. Smith has helped define the company as an industry recognized award-winning “BEST CRO.” He has previously worked for small and large privately held companies in real estate, publishing, and pharmaceutical industries with a consistent focus on client needs and providing high levels of customer service. Mr. Smith received his degree in business administration and marketing from Virginia Tech.

William E. Gannon, Jr. MD, MBA, Medical Advisor

Dr. Gannon has spent much of his career holding the positions of Director of Medical Affairs or Director/Vice President of Clinical Development with biotech, small and mid pharma companies. He is an expert in the development, regulatory NDA –BLA - ANDA – IND – IDE – PMA – 510K FDA submissions and approvals, commercialization, marketing and management of products and technologies for the healthcare, medical devices, allied health and pharmaceutical industries. He has diverse product experience spanning all major medical specialties and innovative health care practices including a focus on vaccines. Dr. Gannon also has experience with European (ISO 9000), Canadian and Japanese regulatory environments, and with IBC AHA and JCAHO regulatory affairs processes.

Gil Price, MD, Medical Advisor, Medical Monitor

Dr. Price is responsible for medical monitoring Accelovance studies, safety management, protocol development and review, regulatory filings, and operating procedures. Over the past 20 years, Dr. Price worked in various medical affairs capacities with pharmaceutical and vaccine companies such as GlaxoSmithKline, MedImmune and Hollis-Eden in addition to establishing his own safety management company.

In previous roles, he was responsible for professional communication, clinical development, business development, pharmacovigilance, medical monitoring, and study design and implementation across various therapeutic areas. His safety management experience includes protocol development for phase I through IV trials and post-marketing in the therapeutic areas of oncology, ophthalmology, anesthetics, anti-infectives, anticoagulants, asthma, respiratory, cardiac and cardiovascular, epilepsy, Crohn’s disease, myelosuppression, hematology, orthopedics, urology, and vaccine therapies for tuberculosis and typhoid fever.

Daniel H. Brune, MD, Medical Director, Accelovance, Peoria

For the past 30 years, Dr. Brune, M.D., has been practicing medicine and helping improve the health of families. A board-certified family practice physician, he balances his private-practice duties with serving as an Investigator for clinical trials. Since his first involvement with clinical trials in 1992, Dr. Brune has conducted more than 115 studies in 29 different medical indications. His experience and commitment to discovering new, more effective and safe pharmaceuticals have made Dr. Brune an integral member to the success of Accelovance’s site network.

John Holaday, PhD, Scientific Advisor, Board Member

Dr. Holaday, Ph.D., has extensive experience building specialty pharmaceutical companies, holds over 30 patents, is an officer and fellow in several biomedical societies, and has authored and edited over 200 scientific articles in journals and books.

Dr. Holaday has founded or co-founded the following companies: EntreMed Inc. (NASDAQ: ENMD), Medicis Pharmaceutical Corp. (NYSE: MRX), and MaxCyte Inc., a cell therapy company. He also sits on the boards of CytImmune Sciences Inc., a privately held cancer research company, and Xceleron, a private UK firm that accelerates clinical trials.

From 1968 to 1989, Dr. Holaday served as a Captain in the U.S. Army and subsequently as a senior civilian employee at the Walter Reed Army Institute of Research, where he founded the Neuropharmacology Branch in 1980. Dr. Holaday currently serves as managing director and CEO of QRx Pharma, a specialty pharmaceutical company focused on new treatments for pain management and central nervous system disorders.